Risk factor
Very high price volatility
Profitability factor
Very low or no dividends
About
Codexis, Inc. discovers, develops, and sells enzymes and other proteins. It offers biocatalyst products and services; intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. It sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.
Company Valuation
From both historical and forecast perspectives, the stock is fairly priced compared to similar stocks.
Target Price
The average target price of CDXS is 6.2 and suggests 161% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increa
Buy
Sell